title: Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
abstract: Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.
authors.affiliation: University of Birmingham CRC Institute for Cancer Studies, Queen Elizabeth Hospital, UK.
authors.forename: D J
authors.initials: DJ
authors.lastname: Kerr
authors.forename: G J
authors.initials: GJ
authors.lastname: Rustin
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
authors.forename: P
authors.initials: P
authors.lastname: Selby
authors.forename: N M
authors.initials: NM
authors.lastname: Bleehen
authors.forename: P
authors.initials: P
authors.lastname: Harper
authors.forename: M H
authors.initials: MH
authors.lastname: Brampton
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D007783:Lactones / Q000627:therapeutic use; D018942:Macrolides; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D007783:Lactones; D018942:Macrolides; C041443:rhizoxin